Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH)

3.70
Delayed Data
As of Apr 29
 -0.10 / -2.63%
Today’s Change
2.28
Today|||52-Week Range
11.65
-20.26%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$148.0M

Company Description

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis. It develops phase 3 product candidates, which includes blisibimod and liprotamase. Anthera Pharmaceuticals was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.

Contact Information

Anthera Pharmaceuticals, Inc.
25801 Industrial Boulevard
Hayward California 94545
P:(510) 856-5600
Investor Relations:
151085656005621

Employees

Shareholders

Other institutional29.66%
Mutual fund holders18.91%
Individual stakeholders0.63%

Top Executives

Paul F. TruexChief Executive Officer & Director
John Craig ThompsonPresident & Chief Operating Officer
May LiuCAO, Senior VP-Finance & Administration
Chuck OlsonChief Technology Officer
James E. PenningtonChief Medical Officer